Key facts
- This page summarizes Benjamin Hohl's Form 4 filing for Enliven Therapeutics, Inc. (ELVN).
- 5 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 07 Jan 2025, 16:43.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Options Exercise
Sale
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Options Exercise
Additional SEC filing notes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Footnote F1
The 1,000 share option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
Footnote F2
This transaction was executed in multiple trades at prices ranging from $25.00 to $25.045. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Footnote F3
The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter.
Footnote F4
The number of derivative securities beneficially owned following the option exercise was as of December 13, 2024 and does not reflect subsequent option exercises that occurred on December 27, 2024 and December 30, 2024 as reported in a Form 4 filed by the Reporting Person on December 31, 2024.
Footnote F5
The number of derivative securities beneficially owned following the option exercise is as of January 3, 2025 and reflects the option exercise that occurred December 13, 2024, and reported herein, and subsequent option exercises that occurred on December 27, 2024 and December 30, 2024 as reported in a Form 4 filed by the Reporting Person on December 31, 2024